Helus Pharma Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
7.67
-1.20 (-13.53%)
At close: Nov 16, 2026, 4:00 PM EST
8.00
+0.33 (4.30%)
Pre-market: Nov 17, 2026, 5:59 AM EST

Helus Pharma Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Helus Pharma stock has a consensus rating of "Strong Buy" and an average price target of $45.54. The average 1-year stock price forecast is 493.74% higher than the current stock price, while the lowest is $14.83 (+93.35%) and the highest is $79.06 (+930.77%).

Price Target: $45.54 (+493.74%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$14.83$45.54$45.12$79.06
Change+93.35%+493.74%+488.27%+930.77%

Analyst Ratings

The average analyst rating for Helus Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy91010101010
Buy000111
Hold000000
Sell000000
Strong Sell000000
Total91010111111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Lucid Capital
Lucid Capital
Buy
Maintains
$52 → $79
BuyMaintains$52 → $79+929.99%Nov 16, 2026
Jefferies
Jefferies
Buy
Maintains
$22
BuyMaintains$22+186.83%Nov 16, 2026
Barclays
Barclays
Buy
Maintains
$35
BuyMaintains$35+356.32%Nov 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$60 → $70
BuyReiterates$60 → $70+812.65%Nov 16, 2026
Unknown Analyst
Guggenheim
No rating
Guggenheim
Buy
Reiterates
$45
BuyReiterates$45+486.70%Oct 23, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
16.56M
EPS This Year
-3.80
from -4.14
EPS Next Year
-2.04
from -3.80
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingMar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Mar 31, 2026Mar 31, 2027
Revenue
------
Operating Income
-51.13M-38.08M-58.22M-103.13M-142.59M-238.18M
Net Income
-54.17M-35.10M-57.66M-81.61M-148.00M-210.54M
EPS
-----4.14-3.80
Free Cash Flow
-----133.81M-170.73M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202720282029
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20282029
High-
Avg-
Low-

EPS Forecast

EPS202720282029
High-3.49
Avg-3.80
Low-4.39

EPS Growth

EPS Growth202720282029
High-
Avg-
Low-